Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 68-year-old man with a history of ischemic cardiomyopathy (left ventricular ejection fraction 25%) and paroxysmal atrial fibrillation presents to the cardiology clinic for follow-up. Over the past month, he has experienced progressive fatigue and frequent palpitations. His current medications include sacubitril-valsartan, carvedilol, eplerenone, dapagliflozin, and apixaban. Vital signs today are within normal limits except for an irregular pulse of 118/min. An electrocardiogram confirms atrial fibrillation with a rapid ventricular response. Given his heavy symptomatic burden and underlying structural heart disease, the physician decides to initiate oral amiodarone for rhythm control. Which of the following baseline diagnostic studies are strictly indicated prior to or shortly after initiating this medication? (Select exactly 3 options)

  1. Thyroid-stimulating hormone (TSH)Answer
  2. Serum aminotransferases (ALT/AST)Answer
  3. Pulmonary function testing with diffusion capacity for carbon monoxide (DLCO)Answer
  4. D
    Prothrombin time (PT) and International Normalized Ratio (INR)
  5. E
    Non-contrast computed tomography (CT) of the chest
  6. F
    Routine slit-lamp ophthalmologic examination

Answer

The necessary baseline diagnostic studies before initiating amiodarone are Thyroid-stimulating hormone (TSH), Serum aminotransferases (ALT/AST), and Pulmonary function testing with diffusion capacity for carbon monoxide (DLCO).
Amiodarone is a highly effective antiarrhythmic agent frequently used in patients with structural heart disease, but it carries a significant risk of systemic toxicity. Baseline evaluation is mandatory to establish reference values prior to exposure. Amiodarone is highly lipid-soluble and contains large amounts of iodine, leading to both hypothyroidism and hyperthyroidism; thus, baseline and periodic thyroid-stimulating hormone (TSH) monitoring is necessary. Hepatotoxicity can also occur, requiring baseline and ongoing serum aminotransferases (ALT/AST). Most critically, amiodarone pulmonary toxicity (APT) is a potentially fatal complication. Establishing a baseline with pulmonary function tests (PFTs), specifically including the diffusion capacity for carbon monoxide (DLCO), along with a standard chest radiograph, is crucial for future comparison if the patient develops respiratory symptoms.

Step-by-Step Solution

1
Identify the primary clinical intervention.
The patient is being initiated on oral amiodarone for symptomatic atrial fibrillation in the setting of structural heart disease.
Recognizing the specific pharmacotherapy dictates the subsequent baseline monitoring protocols.
2
Determine the end-organ toxicities associated with the initiated medication.
Amiodarone is known to cause pulmonary toxicity, hepatotoxicity, and thyroid dysfunction.
Understanding the adverse effect profile is necessary to select appropriate baseline investigations.
3
Select the guideline-recommended baseline studies corresponding to these toxicities.
Guidelines mandate baseline assessment of pulmonary function (PFTs with DLCO), hepatic function (LFTs), and thyroid function (TSH).
Establishing a baseline is critical for differentiating drug toxicity from underlying disease progression if symptoms develop later.
4
Rule out unnecessary tests and inappropriate drug interaction protocols.
Exclude PT/INR (patient is on apixaban, not warfarin), chest CT (chest X-ray is the appropriate baseline), and slit-lamp exam (only done if symptomatic).
Prevents overutilization of healthcare resources and misapplication of clinical guidelines.

Key Concept

Amiodarone Baseline and Ongoing Monitoring Requirements
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic